Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors |
| |
| Authors: | Kempf Dale J Waring Jeffrey F Morfitt David C Werner Paige Ebert Brian Mitten Michael Nguyen Bach Randolph John T DeGoey David A Klein Larry L Marsh Kennan |
| |
| Affiliation: | Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064, USA. dale.kempf@abbott.com |
| |
| Abstract: | A practical preclinical model for the hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors has been developed. Indinavir and atazanavir produced significant hyperbilirubinemia, whereas amprenavir, the negative control, was indistinguishable from the ritonavir booster dose. This model was used to disqualify an exploratory protease inhibitor from development. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
